June 2022 updates to the website
15 June 2022
The website has now been updated following June's LSCMMG
The following guidelines have been added/updated:
Degaralix prescriber information sheet - updated
Hydroxychloroquine prescriber information sheet - updated
Ivabradine prescriber information sheet - updated
Melatonin prescriber information sheet - updated
Clopidogrel tablets after a stroke or mini-stroke information sheet - removed
Ciclosporin shared care guidance - update to follow
The following Items have been updated and added to the website following the latest Strategic Commissioning Committee (SCC) Meeting:
Progesterone capsules - Progestogenic opposition of oestrogen HRT in women with an intact uterus
Ozurdex (dexamethasone intravitreal implant) - for adult patients who have visual impairment due to diabetic macular oedema (DME) who are not pseudophakic or who are considered insufficiently responsive to, or unsuitable for non-corticosteroid therapy
Trimbow NEXThaler - COPD
Fremanezumab - preventing migraine (NICE TA764)
Upadacitinib - treating active psoriatic arthritis after inadequate response to DMARDs (NICE TA768)
Palforzia - treating peanut allergy in children and young people (NICE TA769)
Empagliflozin - for treating chronic heart failure with reduced ejection fraction (NICE TA773)
Dapagliflozin - treating chronic kidney disease (NICE TA775)
The following Items will be updated and added to the website following the next Strategic Commissioning Committee (SCC) Meeting:
Liothyronine - Add-on treatment for refractory hypothyroidism despite adequate replacement with levothyroxine – new patients
Liothyronine - Add-on treatment for refractory hypothyroidism – existing patients.
Liothyronine - Liothyronine monotherapy for the management of chronic hypothyroidism – primary and secondary care